A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
2009
Combining AVE1642 with Bortezomib for Myeloma Treatment
publication
Evidence: moderate
Author Information
Author(s): Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, Amiot M
Primary Institution: Centre de recherches en Cancérologie Nantes/Angers, INSERM, UMR 892, UFR Médecine et Techniques Médicales, Université de Nantes
Hypothesis
Does the combination of AVE1642 and Bortezomib enhance apoptosis in CD45neg myeloma cells?
Conclusion
The combination of AVE1642 and Bortezomib significantly enhances apoptosis in CD45neg myeloma cells.
Supporting Evidence
- AVE1642 significantly enhanced bortezomib-induced apoptosis in all CD45neg HMCLs.
- The combination of AVE1642 and bortezomib was more effective than either treatment alone.
- Noxa expression increased with the combination treatment, correlating with higher apoptosis rates.
Takeaway
This study shows that using two treatments together can help kill more cancer cells in a specific type of blood cancer.
Methodology
The study used human myeloma cell lines to test the effects of AVE1642 and Bortezomib on apoptosis induction.
Statistical Information
P-Value
0.042
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website